 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
| More National Coverage for MJNA Subsidiary |
|
 Hot Stock to Watch |
Company: Medical Marijuana Inc. (Pink Sheets: MJNA)
|
Last:
Price: 0.146
Change (%): + 0.003 (2.10)
Volume: 216,568 |
 |
National News Coverage for KannaLife Sciences, Inc. an MJNA Portfolio Company
FDA Approved Cannabis-Based Drug Development Fuels Discussions Regarding NFL Players, Concussions, and CTE
SAN DIEGO, Dec. 2, 2014 (GLOBE NEWSWIRE) - News of a potential NFL lawsuit settlement and KannaLife Sciences, Inc. (“KannaLife”) license from National Institutes of Health - Office of Technology Transfer (“NIH-OTT”) to develop one or more cannabinoid based drugs to treat Chronic Traumatic Encephalopathy (CTE) has fueled national attention. In addition to the attention received by KannaLife and retired National Football League (“NFL”) star Marvin Washington, now a key advisory board member and CTE spokesperson for KannaLife, there remain big questions for the NFL regarding its policy on prescription pain killers and its exclusionary policy on medicinal cannabis for use by players to reduce pain.
NFL players are still facing long-term suspensions for testing positive for traces of marijuana. Oddly, at the center of another NFL controversy is the league’s policy of denial regarding repetitive concussive injury and a serious and related post traumatic syndrome called CTE. In July 2014, NIH-OTT licensed the use of the U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants” (the ‘507 Patent”) to KannaLife for commercial development of a treatment for CTE.
Boston University defines CTE as: “a progressive degenerative disease of the brain found in athletes (and others) with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic subconcussive hits to the head.”
Marvin Washington, has coined the phrase that, “Football in not a contact sport, it’s a collision sport”. He has been speaking regularly on behalf of the players of his era and the more than 4,500 retired NFL players, including himself, who are involved in a lawsuit against the NFL over the debilitating effects of concussions and CTE.
Marvin Washington now advocates that cannabinoids as neuroprotectants “make the game safer” and can protect professional, recreational and child athletes - all without any psychotropic effects or impact on performance. Working together with KannaLife, Marvin Washington is hopeful that therapeutic agents will be available in the near future and it is his desire to share “proof of concept” with the NFL in order for the league to “lead the science” for its current and former players.
Dean Petkanas, CEO of KannaLife Sciences, told Fox News’ Dr. Manny during a recent exclusive Health Talk that his company, “... plans to file an investigational new drug application with the FDA in early 2015.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
